Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two analysts that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $653.23.
A number of research analysts have weighed in on TMO shares. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective for the company in a report on Friday, January 10th. Scotiabank upped their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Bank of America dropped their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st.
View Our Latest Report on Thermo Fisher Scientific
Insiders Place Their Bets
In related news, CFO Stephen Williamson sold 9,825 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last 90 days. 0.34% of the stock is owned by company insiders.
Institutional Trading of Thermo Fisher Scientific
Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after buying an additional 127,564 shares during the period. Coldstream Capital Management Inc. grew its stake in Thermo Fisher Scientific by 11.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after purchasing an additional 995 shares in the last quarter. Greenwood Gearhart Inc. increased its holdings in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after purchasing an additional 1,837 shares during the period. Nordea Investment Management AB raised its position in Thermo Fisher Scientific by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares in the last quarter. Finally, S.E.E.D. Planning Group LLC grew its position in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after buying an additional 618 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded up $2.53 during trading on Tuesday, reaching $520.25. 1,099,951 shares of the company traded hands, compared to its average volume of 1,538,823. The stock has a market cap of $196.27 billion, a P/E ratio of 31.47, a PEG ratio of 2.99 and a beta of 0.79. The firm's fifty day simple moving average is $546.15 and its 200 day simple moving average is $555.52. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 12-month low of $493.30 and a 12-month high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.
About Thermo Fisher Scientific
(
Get Free ReportThermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
